Mary K. Caffrey

At the 10th anniversary meeting of Patient-Centered Oncology Care®, sessions will cover reducing disparities in cancer care, bringing clinical trials closer to the community, and expanding the scope of what the term "precision medicine" means in cancer care.

Frank Martin, PhD, director of research at JDRF, outlines some of the past and current efforts of the organization to support type 1 diabetes prevention therapies.

Frank Martin, PhD, director of research at JDRF, on the organization’s T1Detect screening program and exploring potential causes of type 1 diabetes.

Clinical findings presented at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.

Coverage from the 2017 Spring Live Meeting of the ACO & Emerging Healthcare Delivery Coalition® on May 4-5, 2017, in Scottsdale, Arizona.

The American Association of Diabetes Educators has offered extensive comments to CMS on how Medicare reimbursement of the Diabetes Prevention Program should occur, so that community groups offering the program financially thrive.

How does a state with almost no money launch Medicaid expansion? Louisiana health officials used data they already had, and in doing so, have created a model that could be used elsewhere.

The public interest journalism group ProPublica examined records from 2011 through 2014 and found that not only are HIPAA violations common, but they also typically go unpunished.

Stories about therapy, led by updates on Afrezza, were most popular with readers interested in diabetes care.

An accompanying editorial says doctors are not irresponsible; they lack access to information about patients'prior overdoses.

Moffitt Cancer Center said there's nothing wrong with the drug, but a spokesman said the trial is halted for now pending the outcome of the investigation.

The prior CEO of MannKind attributed slow sales of Afrezza in part to slow reimbursement from insurers.

St. Peter's University Hospital of New Brunswick argued that it will suffer irreparable harm if Horizon's OMNIA plan takes effect in the new year and it is not included in the preferred hospital tier.

The new rule has been issued just as states are cracking down on the practice of balance billing patients who take steps to use in-network hospitals, only to be balanced billed anyway if they are seen by a provider not on their health plan.

With the Affordable Care Act endangered during the first half of 2015, many popular newsroom stories concerned President Obama's signature legislation.

It appears Sanofi will use a priority review voucher to catch up in the process to Novo Nordisk, which submitted an NDA for Xultophy in late September.

The statement from the obstetricians and gynecologists said that there aren't enough certified genetic counselors to meet demand. In a statement, the groups said this will limit access to care if patients must wait for assistance before ordering tests.

The effort aims to prevent diabetes by urging Americans to get annual checkups and know 4 key numbers: BMI, blood pressure, blood sugar, and cholesterol.

PatientsLikeMe received a grant to work with the National Quality Forum to develop patient-reported outcome measures.

The award is believed to be the largest in Indiana under the Americans with Disabilities Act for a person with diabetes.

The statistics are alarming: 61% of all drug overdose deaths in 2014 are from opioid drugs or heroin, which have been called "chemical cousins."

A letter to the Branstad administration said while approval of waivers to allow managed care could be anticipated, there were still too many unresolved issues to allow a transition on January 1, 2016.

Eleven states already ban minors from using tanning beds, and most states have other restrictions such as requiring a parent's permission.

Plans call for enrolling the first students in the of 2019, in a location in Southern California that will be named later.

In updates from FDA, a copycat insulin is approved and final restrictions are lifted on a one-time blockbuster diabetes drug that all but disappeared from the market.

Without measuring diagnostic errors, it will be impossible to hold people accountable and reduce them.

The new drug application says the insulin will be faster-acting, but it does not say just how fast.